Erythropoietin for end-stage renal disease - PubMed (original) (raw)

Editorial

Erythropoietin for end-stage renal disease

J W Adamson et al. N Engl J Med. 1998.

No abstract available

PubMed Disclaimer

Comment on

• Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients.
  Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG, Kleinman JG, Vaamonde CA. Kaufman JS, et al. N Engl J Med. 1998 Aug 27;339(9):578-83. doi: 10.1056/NEJM199808273390902. N Engl J Med. 1998. PMID: 9718376 Clinical Trial.
• The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.
  Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA. Besarab A, et al. N Engl J Med. 1998 Aug 27;339(9):584-90. doi: 10.1056/NEJM199808273390903. N Engl J Med. 1998. PMID: 9718377 Clinical Trial.

Similar articles

• The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.
  Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA. Besarab A, et al. N Engl J Med. 1998 Aug 27;339(9):584-90. doi: 10.1056/NEJM199808273390903. N Engl J Med. 1998. PMID: 9718377 Clinical Trial.
• Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients.
  Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG, Kleinman JG, Vaamonde CA. Kaufman JS, et al. N Engl J Med. 1998 Aug 27;339(9):578-83. doi: 10.1056/NEJM199808273390902. N Engl J Med. 1998. PMID: 9718376 Clinical Trial.
• A comparison between once-weekly and twice- or thrice-weekly subcutaneous injection of epoetin alfa: results from a randomized controlled multicentre study.
  Lee YK, Kim SG, Seo JW, Oh JE, Yoon JW, Koo JR, Kim HJ, Noh JW. Lee YK, et al. Nephrol Dial Transplant. 2008 Oct;23(10):3240-6. doi: 10.1093/ndt/gfn255. Epub 2008 May 9. Nephrol Dial Transplant. 2008. PMID: 18469158 Clinical Trial.
• What is needed to achieve a hemoglobin of 11.0-13.0 g/dl in end-stage renal disease.
  Fishbane S. Fishbane S. Blood Purif. 2007;25(1):53-7. doi: 10.1159/000096398. Epub 2006 Dec 14. Blood Purif. 2007. PMID: 17170538 Review.
• Management of the chronic renal failure patient receiving epoetin alfa for the treatment of anemia.
  Binkley LS. Binkley LS. Transplant Proc. 1991 Apr;23(2):1831-2. Transplant Proc. 1991. PMID: 2053169 Review. No abstract available.

Cited by

• Erythropoietin: A Personal Alice in Wonderland Trip in the Shadow of the Giants.
  Migliaccio AR. Migliaccio AR. Biomolecules. 2024 Mar 27;14(4):408. doi: 10.3390/biom14040408. Biomolecules. 2024. PMID: 38672425 Free PMC article. Review.
• Treatment of Iron Deficiency Anemia in CKD and End-Stage Kidney Disease.
  Gutiérrez OM. Gutiérrez OM. Kidney Int Rep. 2021 Jun 5;6(9):2261-2269. doi: 10.1016/j.ekir.2021.05.020. eCollection 2021 Sep. Kidney Int Rep. 2021. PMID: 34514189 Free PMC article. Review.
• Markers of iron status in chronic kidney disease.
  Gaweda AE. Gaweda AE. Hemodial Int. 2017 Jun;21 Suppl 1(Suppl 1):S21-S27. doi: 10.1111/hdi.12556. Epub 2017 Mar 22. Hemodial Int. 2017. PMID: 28328097 Free PMC article. Review.
• The role of glucocorticoid receptor (GR) polymorphisms in human erythropoiesis.
  Varricchio L, Migliaccio AR. Varricchio L, et al. Am J Blood Res. 2014 Dec 15;4(2):53-72. eCollection 2014. Am J Blood Res. 2014. PMID: 25755906 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information